UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 735

Sortiert nach

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

Clinical cancer research, 2008-03, Vol.14 (6), p.1649-1657

2008

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2017-02, Vol.389 (10068), p.519-527

2017

Link zum Volltext

Verfügbarkeit prüfen

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Cancer, 2020-07, Vol.126 (14), p.3192-3201

2020

Link zum Volltext

Verfügbarkeit prüfen

Proteasome inhibitors in multiple myeloma: 10 years later

Blood, 2012-08, Vol.120 (5), p.947-959

2012

Link zum Volltext

Verfügbarkeit prüfen

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

Cancer cell, 2013-09, Vol.24 (3), p.275-277

Orlowski, Robert Z.

2013

Link zum Volltext

Verfügbarkeit prüfen

Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

Pharmaceuticals (Basel, Switzerland), 2023-04, Vol.16 (4), p.590

2023

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Blood, 2015-11, Vol.126 (20), p.2284-2290

2015

Link zum Volltext

Verfügbarkeit prüfen

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Blood, 2011-11, Vol.118 (18), p.4771-4779

2011

Link zum Volltext

Verfügbarkeit prüfen

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

Blood, 2015-11, Vol.126 (22), p.2475-2478

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Blood, 2017-03, Vol.129 (12), p.1658-1668

2017

Link zum Volltext

Verfügbarkeit prüfen

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Cell metabolism, 2021-01, Vol.33 (1), p.78-93.e7

2021

Link zum Volltext

Verfügbarkeit prüfen

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

Blood, 2014-04, Vol.123 (14), p.2204-2208

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Blood, 2013-10, Vol.122 (18), p.3122-3128

2013

Link zum Volltext

Verfügbarkeit prüfen

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

Cancer cell, 2013-12, Vol.24 (6), p.791-805

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Clinical cancer research, 2009-11, Vol.15 (22), p.7085-7091

2009

Link zum Volltext

Verfügbarkeit prüfen

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Blood, 2019-04, Vol.133 (14), p.1572-1584

2019

Link zum Volltext

Verfügbarkeit prüfen

The proteasome and proteasome inhibitors in cancer therapy

Annual review of pharmacology and toxicology, 2006-01, Vol.46 (1), p.189-213

2006

Link zum Volltext

Verfügbarkeit prüfen

The Immunoproteasome as a Target in Hematologic Malignancies

Seminars in hematology, 2012-07, Vol.49 (3), p.258-262

2012

Link zum Volltext

Verfügbarkeit prüfen

Proteasome inhibitors in cancer therapy

Nature reviews. Clinical oncology, 2017-07, Vol.14 (7), p.417-433

2017

Link zum Volltext

Verfügbarkeit prüfen

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

Blood, 2014-10, Vol.124 (17), p.2687-2697

2014

Link zum Volltext

Verfügbarkeit prüfen

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Blood, 2007-11, Vol.110 (9), p.3281-3290

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 735

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(693)
Mit Volltextzugriff
(701)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(272)
Life Sciences & Biomedicine
(267)
Humans
(238)
Oncology
(154)
Hematology
(148)
Multiple Myeloma
(139)
Female
(119)
Multiple Myeloma - Drug Therapy
(116)
Male
(107)
Middle Aged
(100)
Aged
(95)
Bortezomib
(88)
Adult
(76)
Treatment Outcome
(63)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(59)
Multiple Myeloma - Pathology
(54)
Biological And Medical Sciences
(53)
Animals
(52)
Medical Sciences
(52)
Aged, 80 And Over
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Proteasome inhibitors in multiple myeloma: 10 years later

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

The proteasome and proteasome inhibitors in cancer therapy

The Immunoproteasome as a Target in Hematologic Malignancies

Proteasome inhibitors in cancer therapy

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Suchergebnisse filtern